Biogen, Inc. (BIIB)
250.69
-3.15
(-1.24%)
USD |
NASDAQ |
Oct 23, 16:00
247.18
-3.51
(-1.40%)
After-Hours: 20:00
Biogen Price to Book Value : 1.964 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.964 |
| October 22, 2026 | 1.989 |
| October 21, 2026 | 1.888 |
| October 20, 2026 | 1.905 |
| October 19, 2026 | 1.830 |
| October 16, 2026 | 1.823 |
| October 15, 2026 | 1.844 |
| October 14, 2026 | 1.824 |
| October 13, 2026 | 1.794 |
| October 12, 2026 | 1.798 |
| October 09, 2026 | 1.769 |
| October 08, 2026 | 1.712 |
| October 07, 2026 | 1.741 |
| October 06, 2026 | 1.747 |
| October 05, 2026 | 1.752 |
| October 02, 2026 | 1.723 |
| October 01, 2026 | 1.746 |
| September 30, 2026 | 1.770 |
| September 29, 2026 | 1.779 |
| September 28, 2026 | 1.792 |
| September 25, 2026 | 1.784 |
| September 24, 2026 | 1.774 |
| September 23, 2026 | 1.783 |
| September 22, 2026 | 1.766 |
| September 21, 2026 | 1.717 |
| Date | Value |
|---|---|
| September 18, 2026 | 1.689 |
| September 17, 2026 | 1.717 |
| September 16, 2026 | 1.693 |
| September 15, 2026 | 1.694 |
| September 14, 2026 | 1.703 |
| September 11, 2026 | 1.702 |
| September 10, 2026 | 1.688 |
| September 09, 2026 | 1.651 |
| September 08, 2026 | 1.665 |
| September 04, 2026 | 1.730 |
| September 03, 2026 | 1.759 |
| September 02, 2026 | 1.745 |
| September 01, 2026 | 1.693 |
| August 31, 2026 | 1.698 |
| August 28, 2026 | 1.712 |
| August 27, 2026 | 1.736 |
| August 26, 2026 | 1.732 |
| August 25, 2026 | 1.73 |
| August 24, 2026 | 1.709 |
| August 21, 2026 | 1.699 |
| August 20, 2026 | 1.680 |
| August 19, 2026 | 1.736 |
| August 18, 2026 | 1.666 |
| August 17, 2026 | 1.639 |
| August 14, 2026 | 1.644 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AbbVie, Inc. | -- |
| Gilead Sciences, Inc. | 16.37 |
| Amgen, Inc. | 20.32 |
| Ionis Pharmaceuticals, Inc. | 16.17 |
| Regeneron Pharmaceuticals, Inc. | 2.625 |
Price to Book Value Related Metrics
| PE Ratio | 44.40 |
| PS Ratio | 3.833 |
| Price to Free Cash Flow | 14.87 |
| Price | 250.69 |
| Earnings Yield | 2.25% |
| Market Cap | 37.03B |
| Operating PE Ratio | 19.66 |
| Normalized PE Ratio | 27.44 |